Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Still, it is wise to treat anyone with severe gastrointestinal symptoms as if they could have norovirus, prompting those ...

GLP1 receptor agonists are widely prescribed to help control blood sugar levels and support weight loss. While these ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Drugmaker Abbott India reported a jump in third-quarter profit on Wednesday, helped by strong demand for its gastrointestinal and heart disease medications, sending shares higher.

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for ...

Histamine intolerance is a proposed condition in which a person may have difficulty metabolizing histamine in food. Learn ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...